NCT03085810

Who might be able to join this trial:

• You have been officially diagnosed with relapsing-remitting multiple sclerosis (RRMS) using a specific standard diagnostic method called the McDonald 2010 criteria
• Your MS was first diagnosed or first showed clear symptoms no more than 3 years ago
• In the past 12 months, you have had at least one MS relapse (flare-up) or at least one sign of MS activity shown on an MRI scan
• Your level of physical disability, measured by a standard MS scale, falls within a mild range at the time of screening (confirm with trial site)
• If you are a woman who could become pregnant, you agree to use an acceptable form of birth control during the study and for at least 6 months after your last dose of the study drug

Who may not be able to join:

• You have a form of MS that is progressively worsening, such as secondary progressive, primary progressive, or progressive relapsing MS
• You are unable to have an MRI scan for any reason
• You have another known neurological condition affecting your brain or nervous system
• You are currently pregnant or breastfeeding
• You are planning to become pregnant during the study or within 6 months of your last dose of the study drug
• You have another illness that requires long-term use of steroid medications or immune-suppressing drugs
• You have a current or past condition where your immune system does not work properly (immunodeficiency)
• Veins in your arm cannot be accessed easily enough for an IV drip
• You have had a serious allergic reaction, including anaphylaxis, to certain types of antibody-based medicines in the past
• You have another significant or uncontrolled illness that may make it unsafe for you to participate
• You have moderate to severe heart failure (confirm with trial site)
• You currently have an active infection (bacterial, viral, fungal, or other), or you were hospitalised for an infection or treated with intravenous antibiotics within the past 4 weeks, or took oral antibiotics within the past 2 weeks
• You have a history of cancer, serious opportunistic infections, alcohol or drug misuse, recurring or long-term infections, or blood clotting disorders
• You have previously taken any approved MS disease-modifying medication, including drugs such as interferons, glatiramer acetate, natalizumab, alemtuzumab, fingolimod, or dimethyl fumarate, among others
• You received a live or weakened live vaccine within 6 weeks before the start of the study
• You have previously been treated with certain B-cell targeting therapies, such as rituximab, ocrelizumab, or similar drugs
• You have previously received certain immune-suppressing, immune-modifying, or cancer-treating drugs, including but not limited to cyclophosphamide, methotrexate, mitoxantrone, or bone marrow transplantation
• You are currently taking part in another MS drug trial
• You are taking a medication called fampridine/dalfampridine and your dose has not been stable for at least 30 days before screening
• You have previously had a serious infusion reaction during treatment with ocrelizumab (this applies to a specific part of the study — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.